| 1 |
35142429 | Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression. | 2022 Feb |
1 |
| 2 |
33896692 | Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients. | 2021 Apr 19 |
2 |
| 3 |
34691254 | Sorafenib treatment of metastatic melanoma with c-Kit aberration reduces tumor growth and promotes survival. | 2021 Dec |
1 |
| 4 |
34781982 | STOML2 interacts with PHB through activating MAPK signaling pathway to promote colorectal Cancer proliferation. | 2021 Nov 15 |
1 |
| 5 |
32114388 | ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation. | 2020 Mar |
1 |
| 6 |
32181767 | [vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors]. | 2020 Mar 17 |
1 |
| 7 |
33202899 | Combination Antitumor Effect of Sorafenib via Calcium-Dependent Deactivation of Focal Adhesion Kinase Targeting Colorectal Cancer Cells. | 2020 Nov 13 |
1 |
| 8 |
33255818 | Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation. | 2020 Nov 25 |
1 |
| 9 |
30456603 | The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling. | 2019 Oct |
1 |
| 10 |
30509084 | The AT1/Raf/ERK1/2 signaling pathway is involved in Angiotensin II-enhanced proliferation of hepatic carcinoma cells. | 2019 Jan 15 |
1 |
| 11 |
30557787 | Biosynthesis of sorafenib coated graphene nanosheets for the treatment of gastric cancer in patients in nursing care. | 2019 Feb |
1 |
| 12 |
30586319 | Localization dynamics of endogenous fluorescently labeled RAF1 in EGF-stimulated cells. | 2019 Feb 15 |
1 |
| 13 |
30962952 | The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma. | 2019 |
1 |
| 14 |
31029219 | Sorafenib. | 2019 |
1 |
| 15 |
31385002 | Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. | 2019 Oct |
2 |
| 16 |
32743370 | Successful treatment with sorafenib for sunitinib-refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib. | 2019 Jan |
4 |
| 17 |
29156516 | Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway. | 2018 Jan |
2 |
| 18 |
29251327 | Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. | 2018 Feb |
3 |
| 19 |
29423069 | Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option. | 2018 Jan 9 |
1 |
| 20 |
29436591 | Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals. | 2018 May |
2 |
| 21 |
29484394 | Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line. | 2018 Apr |
2 |
| 22 |
29605720 | Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. | 2018 May |
1 |
| 23 |
29706627 | The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. | 2018 May 1 |
1 |
| 24 |
29858683 | Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. | 2018 Aug |
3 |
| 25 |
30317792 | [Mechanism of angiotensin II (Ang II) on the proliferation of human hepatoma cell line HepG2 cells]. | 2018 Aug 20 |
1 |
| 26 |
27936391 | Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients. | 2017 Feb |
6 |
| 27 |
28161506 | Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells. | 2017 Apr 28 |
4 |
| 28 |
28260092 | Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib. | 2017 Apr |
1 |
| 29 |
28276530 | Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. | 2017 Mar 9 |
4 |
| 30 |
28808038 | The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. | 2017 Nov 1 |
1 |
| 31 |
29030911 | Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. | 2017 Dec |
1 |
| 32 |
29113345 | Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems. | 2017 Oct 6 |
3 |
| 33 |
26350096 | RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. | 2016 Jan |
1 |
| 34 |
26364606 | Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. | 2016 May 19 |
1 |
| 35 |
26655273 | MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. | 2016 Feb 28 |
1 |
| 36 |
26861698 | Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. | 2016 Feb 9 |
1 |
| 37 |
26861740 | Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. | 2016 Feb |
1 |
| 38 |
26998658 | Sorafenib for the treatment of multiple myeloma. | 2016 Jun |
2 |
| 39 |
27034005 | Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles. | 2016 May 3 |
1 |
| 40 |
27095937 | Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations. | 2016 |
1 |
| 41 |
27167344 | Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. | 2016 Jun 14 |
2 |
| 42 |
27496136 | Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. | 2016 Nov |
1 |
| 43 |
28000790 | A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis. | 2016 Dec 21 |
1 |
| 44 |
25333206 | Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro. | 2015 Jan |
1 |
| 45 |
25550214 | Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation. | 2015 May |
1 |
| 46 |
25823619 | The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro. | 2015 Jun |
1 |
| 47 |
25862849 | Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression. | 2015 Apr |
1 |
| 48 |
25895026 | Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. | 2015 May 20 |
1 |
| 49 |
26058013 | Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. | 2015 Jun 5 |
1 |
| 50 |
26097571 | SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway. | 2015 |
2 |